<DOC>
	<DOCNO>NCT03066869</DOCNO>
	<brief_summary>The purpose study evaluate short- long-term efficacy safety Acthar treatment adult non-infectious retinal vasculitis .</brief_summary>
	<brief_title>Efficacy Safety H.P . ACTHAR GEL Adults With Retinal Vasculitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Retinal Vasculitis</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Any adult patient active retinal vasculitis ( involve artery vein ) manifestation noninfectious ocular inflammatory disease ; fundus must viewable widefield FA study eye If eye involve , eligible inclusion study Patients already nonsteroidal immunosuppressive therapy may continue study , dose must increase decrease within 6 week initiate trial Willing able sign inform consent form Patients age 18 Patients pregnant ( must rule woman childbearing age ) Active infectious ocular systemic disease Patients active infectious ocular extraocular disease Patients history malignancy , except dermatologic entity basal squamous cell carcinoma completely excise remove previously Patients systemic illness involve abnormality hypothalamicpituitaryadrenal axis ; patient primary adrenocortical insufficiency adrenocortical hyperfunction Patients know hypersensitivity Acthar Patients nonsteroidal systemic immunomodulatory medication dose adjusted sooner 6 week prior study drug administration Patients currently recently treat ( within 6 week ) systemic corticosteroid Patients periocular intraocular injection medication administer help control inflammation sooner 6 week prior study drug administration Patients severe disease warrant critical attention , deem unsafe study investigator , contraindicate , include limited , patient scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex , recent surgery , history presence peptic ulcer , congestive heart failure , uncontrolled hypertension , sensitivity protein porcine origin . Administration live live attenuate vaccine contraindicate patient entire duration study one month prior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>